| Cardiovascular diseases are diseases that seriously endanger human health. In recent years,the incidence and mortality of the diseases have risen steadily in both western and eastern countries and gradually become the primary killer of human health. With the development of medical science, people realize that high cholesterol and high lipid are the basic causes of cardiovascular diseases, dyslipidemia is the main risk factors of coronary heart disease and hypertension. Therefore, people begin to focus on develop medicine that regulate lipid as key prevention of cardiovascular diseases. Since late 1980s, huge amount of cholesterol-lowering drugs were presented, statins are used on clinical widely by doctors, they have clinical efficacy that are not comparable by other types of cholesterol-lowering. So the research and development of statins has been high concerned people. Our study used Rosuvastatin, the newest kind of statins, it has outstanding efficacy in lowering low-density lipoprotein-cholesterol (LDL-C) and high-density lipoprotein- cholesterol (HDL-C), thus reduce the incidence of cardiovascular events by regulating lipid level.Aim: To evaluate the efficacy and safety of rosuvastatin in treating hyperlipidemia by using atorvastatin as control.Method: We used randomized, double-blind, double simulation, positive drugs parallel control study, and the control group was atorvastatin manufactured by Pfizer. We randomly divided participants into Rosuvastatin5mg group with 5mg rosuvastatin administrated (n=35), Rosuvastatin10mg group 2 with 10mg rosuvastatin administrated (n=35), control group with 10mg atorvastatin (n=35) , the treatment last for 12 weeks. All three group administrated drug once at 8 p.m. daily. Blood lipid and other biochemical index were obtained before test, 4 weeks, 8 weeks and 12 weeks after test respectively. The efficacy and safety of lipid regulation were observed and compared between each groups, then statistic study to the data . Results:The blood serum total cholesterol (TC) decreased after 4 weeks of administration of all three groups, Rosuvastatin5mg group, Rosuvastatin10mg group and control group, that is 28.26% and 22.86%, 27.21% respectively; and 26.41%, 31.16% and 25.67% respectively after 8 weeks of administration; 26.16%, 31.94% 27.23% respectively after 12 weeks, the TC level of three groups reduced significantly TC level. Rosuvastatin10mg group is better in TC lowering than Rosuvastatin5mg group and control group. 4 weeks after administration, blood LDL-C level decreased 33.98%, 38.40% and 35.74% respectively to Rosuvastatin5mg group, Rosuvastatin10mg group and control group; 37.95%, 39.83% and 39.32% respectively after 8 weeks; and 35.29%, 40.80% and 35.74% at the end of 12th week, the LDL-C level reduced significantly. Rosuvastatin10mg group is better in LDL-C lowering compare to Rosuvastatin 5mg group and control group. The blood HDL-C level increased after 4 weeks of administration of all three groups, that is 5.26%,6.25% and 0% respectively; and 0%, 0% and 0.67% respectively after 8 weeks of administration; 2.26%, 7.14% increasing of Rosuvastatin5mg group and Rosuvastatin10mg group but reduction of 3.11% for control group after 12 weeks of administration. the HDL-C level of study groups are significantly increased but not for control group. 4 weeks after administration, blood Total triglycerides (TG) level decreased 21.40%, 17.15% and 21.49% respectively to Rosuvastatin5mg group, Rosuvastatin10mg group and control group; 19.01%,21.55% and15.50% respectively after 8 weeks; and 12.26%, 22.88% and 24.49% at the end of 12th week respectively, the TG level reduced significantly. The rate of side effects occurrence of study group1 is 5.71%, study group 2 is 8.57% and control group is 8.57%, there is no significant difference (P>0.05)Conclusion: Compare to atorvastatin, rosuvastatin can effectively reduced TC,LDL-C,TG level and increase HDL-C level, and is safety to use. |
